Evidence map›Paper›PMID 36099123›Full record

ArticleIn vivo (Athens, Greece)

A Mouse Model for Tuberculosis Combined With Inhalable Imiquimod-PLGA Nanocomposite Particles Based on Macrophage Phenotype.

Teruki Nii, Shunsuke Takizawa, Tomomi Akita, Chikamasa Yamashita, Issei Takeuchi, Kimiko Makino

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Teruki NiiDepartment of Applied Chemistry, Faculty of Engineering, Kyushu University, Fukuoka, Japan; nii.teruki.204@m.kyushu-u.ac.jp takeuchi@rs.tus.ac.jp.
Shunsuke TakizawaFaculty of Pharmaceutical Sciences, Tokyo University of Sciences, Yamazaki, Japan.
Tomomi AkitaFaculty of Pharmaceutical Sciences, Tokyo University of Sciences, Yamazaki, Japan.
Chikamasa YamashitaFaculty of Pharmaceutical Sciences, Tokyo University of Sciences, Yamazaki, Japan.
Issei TakeuchiFaculty of Pharmaceutical Sciences, Tokyo University of Sciences, Yamazaki, Japan; nii.teruki.204@m.kyushu-u.ac.jp takeuchi@rs.tus.ac.jp.
Kimiko MakinoFaculty of Pharmaceutical Sciences, Tokyo University of Sciences, Yamazaki, Japan.
Tokyo University of Science · JPJosai International University · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimIn vivo models of tuberculosis are effective tools for developing new drugs. The objective of this study was to prepare in vivo models for tuberculosis by utilizing nanocomposite particles (NCPs) containing imiquimod-loaded poly(lactic-co-glycolic acid) nanoparticles. MATERIALS AND

methodsNCPs were prepared from dichloromethane with imiquimod and poly(lactic-co-glycolic acid) using a spray dryer. Mice were treated with NCPs in the lungs by inhalation, and then infection with Mycobacterium bovis bacille Calmette-Guerin was performed (treatment groups). The concentrations of the pro-inflammatory cytokines, tumor necrosis factor-α and interferon-γ were measured in bronchoalveolar lavage fluid using an enzyme-linked immunosorbent assay.

resultsWhen animals were treated with NCPs, the concentrations of tumor necrosis factor-α and interferon-γ in bronchoalveolar lavage fluid were significantly higher than in animals not treated with NCPs. In addition, high bacterial counts and circular granuloma were observed.

conclusionNCPs prepared in this study enhanced the level of inflammation in the lungs and support the preparation of in vivo models of tuberculosis.

Indexed as

NanocompositesTuberculosisAnimalsDisease Models, AnimalImiquimodInterferon-gammaLactic AcidMacrophagesMiceParticle SizePhenotypePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor Necrosis Factor-alphaImiquimodInterferon-gammaLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerTumor Necrosis Factor-alphainhalationin vivo modelNanocomposite particlesPLGAtuberculosis

Identifiers

PMID36099123
PMCPMC9463881
OpenAlexW4294904011

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.